BRAF V600E en carcinoma tiroideo anaplásico (ATC, ~25-50% de los casos): dabrafenib + trametina...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BMA-BRAF-V600E-THYROID-ANAPLASTIC |
|---|---|
| Tipo | Relevancia terapéutica |
| Situación | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Enfermedades | DIS-THYROID-ANAPLASTIC |
| Fuentes | SRC-CIVIC SRC-NCCN-THYROID-2025 |
Hechos relativos a la posibilidad de adoptar medidas
| Biomarcador | BIO-BRAF-V600E |
|---|---|
| Variante | V600E (exón 15, dominio de la quinasa — presente en ~25-50% de carcinoma tiroideo anaplásico) |
| Enfermedad | DIS-THYROID-ANAPLASTIC |
| El nivel de ESCAT | IA |
| Combinaciones recomendadas | dabrafenib + trametinib (1L V600E ATC per SRC-NCCN-THYROID-2025), neoadjuvant dabrafenib + trametinib → surgery → adjuvant systemic ± RT (initially unresectable, per SRC-NCCN-THYROID-2025) |
| Monoterapia contraindicada | BRAF Inhibidor de la monoterapia (paradójico) MAPK activación; combinación con MEK inhibidor requerido por SRC-NCCN-THYROID-2025) |
| Resumen de las pruebas | BRAF V600E in anaplastic thyroid carcinoma (ATC, ~25-50% of cases): dabrafenib + trametinib has tumor-agnostic FDA approval for BRAF V600E unresectable/metastatic disease and is preferred 1L for V600E-mutant ATC per SRC-NCCN-THYROID-2025. The pivotal ROAR basket trial (Subbiah JCO 2018 — ATC cohort ORR 69%, mOS ~14 mo, dramatic response in a historically rapid-fatal disease — historical mOS ~5 mo) drove the 2018 FDA accelerated approval (full conversion 2022 with pan-cancer broadening). Consider neoadjuvant dabrafenib+trametinib to enable surgery in initially unresectable V600E ATC per SRC-NCCN-THYROID-2025. |
Notas
ESCAT IA / OncoKB Level 1. ATC is a clinical emergency — initiate BRAF testing on the same day as biopsy diagnosis per SRC-NCCN-THYROID-2025 ("RAID" workflow). Resistance: development of MEK reactivation, alternative MAPK isoforms; triple combination with anti-PD-1 (ATLEP trial) is investigational. Source-gap: SRC-ROAR-SUBBIAH-2018 not yet ingested.
Utilizado por
No se encuentran referencias inversas en el corpus YAML.